A

Aclaris Therapeutics
D

ACRS

1.70000
USD
0.02
(1.19%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
184,078,106
أصول ذات صلة
A
ADAP
0.01530
(4.60%)
0.34760 USD
A
ARWR
-0.520
(-3.20%)
15.740 USD
A
ATRA
-0.440
(-3.61%)
11.760 USD
C
CORT
0.670
(0.99%)
68.260 USD
C
CRIS
0.01500
(0.82%)
1.84000 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
F
FATE
-0.01000
(-0.80%)
1.23500 USD
ICLR
ICLR
-7.920
(-4.06%)
187.080 USD
K
KURA
-0.23500
(-3.64%)
6.22500 USD
V
VKTX
0.960
(2.87%)
34.420 USD
X
XNCR
-0.00500
(-0.05%)
9.23000 USD
المزيد
الأخبار المقالات

العنوان: Aclaris Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.